MIRA
MIRA Pharmaceuticals, Inc. (MIRA) Risks & Opportunities Analysis (2026)
Overall Score
Financial Stability
Very high current ratio of 200.1x and cash ratio of 88.4x indicate an exceptionally liquid balance sheet.
No debt is shown in the latest ratios, with debt-to-assets and debt-to-equity both at 0.0.
Profitability
TTM margins remain at 0.0% across gross, operating, EBITDA, pretax, and net profit, indicating no current operating profitability.
Returns remain deeply negative, with ROA at -1.16%, ROE at -1.07%, and ROIC at -1.15%.
Cash Flow
TTM operating cash flow and free cash flow are both negative, with free cash flow yield at -13.0%.
Cash conversion remains weak despite the high liquidity position, as operating cash flow per share is -0.11 and free cash flow per share is -0.11.
Valuation
The stock screens as asset-backed rather than earnings-backed, with price-to-book at 4.37x and tangible book value per share at 0.19.
Traditional earnings and cash-flow multiples are not meaningful given negative TTM earnings and cash flow, so valuation remains difficult to anchor.
Risk Profile
The main risk is continued operating losses, as profitability and cash generation remain negative across the TTM period.
The balance sheet is liquid, but the negative solvency ratio and weak earnings yield underscore ongoing execution and financing risk.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MIRA Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

